Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vascular and metabolic effects of sunitinib in metastatic renal cell carcinoma
NL-OMON34257Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sunitinib in renal cell carcinoma (RCC) (3 arms), sponsored by Radboud University Medical Center. Primary endpoints: Forearm vasomotor response, Insulin sensitivity and 1 more. Started Nov 2010; status: active, not recruiting.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON34257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34257.